The latest literature reveals a surge of evidence linking GLP-1 RA therapy to cardiovascular protection, MASLD/MASH treatment, weight‑loss outcomes in diverse populations, and emerging safety insights, underscoring a paradigm shift toward broader metabolic and tissue‑specific benefits.
Alzheimer's & dementia (Amsterdam, Netherlands) · Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.
Semaglutide slowed progression of a validated proteomics‑based dementia risk signature, showing up to 2.5‑fold lower predicted 5‑year dementia risk versus placebo.
Diabetes, obesity & metabolism · Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment.
A real‑world cohort of 16,556 adults showed that AI‑driven patient support improved 6‑month adherence to semaglutide/tirzepatide, while non‑adherence was driven by side‑effects and cost.
Diabetes, obesity & metabolism · Glucagon-Like Peptide-1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.
In a large German claims cohort, GLP‑1 RA users had a 9% lower hazard of major adverse liver outcomes compared with SGLT‑2 inhibitor users, with reduced cirrhosis and HCC risk.
Clinical pharmacology and therapeutics · Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.
Retrospective analysis linked tirzepatide to a 18% lower hazard of carpal tunnel syndrome compared with GLP‑1 RA, suggesting broader metabolic benefits beyond glycaemia.
European journal of preventive cardiology · Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
Post‑hoc analysis of SURMOUNT‑1 demonstrated that tirzepatide lowered predicted 10‑year CVD risk by up to 1.9% over 3 years, supporting its use for primary prevention.
Expert review of endocrinology & metabolism · Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.
Review summarizing the efficacy, safety, and implementation challenges of resmetirom and semaglutide for MASLD, emphasizing the need for equitable access and longer‑term data.
Dermatology and therapy · Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of "Ozempic Face".
Survey of 1,226 patients revealed that greater weight loss correlated with higher rates of skin sagging, hair loss, and facial volume reduction, informing patient counseling.
Clinics in dermatology
Review of GLP-1 receptor expression in skin cells and potential direct/indirect skin effects.
Diabetes, obesity & metabolism
Study on patient and prescription factors influencing fill rates of GLP-1 RA obesity treatments.
Childhood obesity (Print)
Short‑term meal replacement reduced hepatic fat and BMI in adolescents with MASLD.
Journal of diabetes investigation
Discussion of muscle health considerations with incretin therapies.
The Journal of clinical endocrinology and metabolism
Guidance on diabetes management across cirrhosis stages, including GLP-1 RA use.
Diabetes, obesity & metabolism
Evaluation of AI‑driven support on adherence to semaglutide/tirzepatide.
Cell metabolism
Low‑protein, methionine‑tuned diet improves metabolic markers and reduces frailty via GH‑GLP‑1‑FGF21 axis.
Obesity pillars
Post‑hoc analysis shows orforglipron yields significant weight loss in adults ≥65 years, with a safety profile consistent with other GLP‑1 RAs.